HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acurox Panel Review Complicated By FDA's Uncertainty Over How Much Evidence Is Needed To Prove Abuse Deterrence

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is not convinced that additives meant to make the immediate-release oxycodone formulation difficult to ingest, snort or inject will have their intended deterrent effect.
Advertisement

Related Content

Quandary Remains In Creating Abuse-Resistant Opioid Painkillers
Quandary Remains In Creating Abuse-Resistant Opioid Painkillers
FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit
FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit
Opioid Risk Management: FDA Not Impressed With Industry Working Group's Proposals
Business In Brief
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS070515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel